Physician profile
Jose Ferrer
NPI 1730281387
$10,449.18
in general payments reported to CMS, 2019-2025
39 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $1,110 · 2021: $1,483 · 2022: $1,581 · 2023: $2,264 · 2024: $1,590 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,431.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.84 | 2019-2025 | |
| Janssen Biotech, INC. | $825.32 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $681.77 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $574.66 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $572.74 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $571.01 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $509.87 | 2020 | |
| Celgene Corporation | $497.66 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $442.22 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Redhill Biopharma INC. | $357.86 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Aimmune Therapeutics, INC. | $289.77 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $261.49 | 2019-2021 | |
| Daiichi Sankyo INC. | $260.99 | 2019-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $202.66 | 2023-2025 | Voquezna |
| Celltrion USA INC. | $183.64 | 2024-2025 | Vegzelma |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $179.48 | 2021-2023 | |
| Gilead Sciences, INC. | $179.18 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $173.02 | 2021-2025 | Ocaliva |
| Boston Scientific Corporation | $148.05 | 2023 | Exalt Model D |
| Evoke Pharma, INC. | $138.22 | 2021-2024 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $138.11 | 2024-2025 | Iqirvo |
| Curium US LLC | $125.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $123.75 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $113.22 | 2022-2024 | Sutab, Suflave |
| Coloplast Corp | $102.40 | 2019 | |
| Madrigal Pharmaceuticals | $86.60 | 2025 | Rezdiffra |
| Lilly USA, LLC | $86.48 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $70.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vivus LLC | $69.61 | 2021-2024 | Qsymia |
| Amgen INC. | $47.80 | 2021-2023 | Avsola |
| Merck Sharp & Dohme LLC | $43.37 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $36.76 | 2020-2022 | |
| Allergan, INC. | $36.61 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $34.40 | 2021-2022 | |
| Novo Nordisk INC | $24.18 | 2025 | Wegovy |
| Covidien Lp | $18.32 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.22 | 2023 | Monoferric |
| Shire North American Group INC | $16.58 | 2019 | |
| Siemens Medical Solutions USA, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ferrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.